News

People with myasthenia gravis (MG) who are positive for antibodies against the acetylcholine receptor (AChR) — the most common MG-causing antibodies — tend to have increased activation of part of the immune system called the complement cascade, according to a recent study. However, increased complement activation was not…

Vyvgart (efgartigimod alfa-fcab) is now approved in Israel for the treatment of generalized myasthenia gravis (gMG), according to its developer, Argenx. This is the second new approval for Vyvgart in gMG this year, following a similar positive decision in the U.K. in March. The therapy has…

Repeated treatment with under-the-skin efgartigimod had a consistent effect in easing symptoms of generalized myasthenia gravis (gMG), with no new safety issues identified.  That’s according to interim data from the Phase 3 extension study ADAPT-SC+ (NCT04818671), which is…

More generalized myasthenia gravis (gMG) patients who received Ultomiris (ravulizumab) in the Phase 3 CHAMPION MG trial achieved a favorable clinical response to treatment relative to those taking a placebo, according to new trial analyses. The proportion of patients achieving that milestone, according to the Myasthenia Gravis Foundation…

People with generalized myasthenia gravis (gMG) treated with the experimental therapy rozanolixizumab in a clinical trial generally experienced reductions in disease severity scores regardless of disease duration, prior treatments, and initial disease severity, new analyses suggest. Findings were presented by Tuan Vu, MD, of the University of South…

Treatment with Vyvgart (efgartigimod alfa-fcab) over two years was found to safely and effectively ease symptoms of generalized myasthenia gravis (gMG) among participants in an open-label extension study, according to an analysis of new data. “This analysis suggests that long-term efgartigimod [Vyvgart] treatment is well tolerated and…

Treatment with the experimental therapy zilucoplan eased symptoms of generalized myasthenia gravis (gMG) across different subgroups of patients participating in the Phase 3 RAISE clinical trial. Trial data showed treatment effects were consistent, regardless of sex, age, disease duration, prior use of certain treatments, or thymoma status. Findings…

Radiotherapy given after surgery to remove the thymus, called a thymectomy, eases symptoms of myasthenia gravis (MG) associated with a thymus tumor, and it can cut in half the time to a considerable recovery, a study from China found. Such recovery, known as minimal manifestation status, was defined as…

People who develop myasthenia gravis (MG) with very late onset — when they’re age 65 or older — may have a poor prognosis, particularly if they haven’t been started on immunotherapy, a study in China has found. These findings shine a light on how important it is to understand…

Robot-assisted surgery to remove the thymus is generally safe for people with myasthenia gravis (MG), with most patients who undergo the procedure seeing a reduction in symptom severity afterward, a study reports. “This retrospective follow-up study showed that robotic thymectomy [thymus removal surgery] is safe and feasible in patients…